2 active not recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adenosine 2A Receptor Antagonism and AIH in ALS Consume 20mg of istradefylline, Low Oxygen therapy, Placebo counterpart to the istradefylline drug - ALS | Phase 1 / Phase 2 | Active not recruiting | University of Florida | 40 | 2022-06-21 | 2026-03-27 |
| Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) Autologous Adipose-derived Mesenchymal Stromal Cells - ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Active not recruiting | Mayo Clinic | 75 | 2017-10-10 | 2026-03-09 |
Amyotrophic Lateral Sclerosis (1) · Hypoxia (1) · Respiratory Aspiration (1)
Central Nervous System Diseases (1) · Metabolic Diseases (1) · Motor Neuron Disease (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Nutritional and Metabolic Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Proteostasis Deficiencies (1) · Respiration Disorders (1) · Respiratory Tract Diseases (1) · Signs and Symptoms (1) · Signs and Symptoms, Respiratory (1) · Spinal Cord Diseases (1)
Insemination, Artificial, Homologous (1) · istradefylline (1)
Mayo Clinic (1) · University of Florida (1)
United States (2)
Anthony J Windebank, MD (1) · Barbara Smith (1) · Nathan P Staff, MD, PhD (1)